Altimmune (NASDAQ: ALT) furnishes Q2 2025 earnings press release in 8-K

Rhea-AI Filing Summary

Altimmune, Inc. filed a current report to furnish a press release announcing its financial results for the second quarter ended June 30, 2025. The press release, dated August 12, 2025, is included as Exhibit 99.1 and is provided for informational purposes rather than being formally filed under securities laws.

0001326190false00013261902025-08-122025-08-12

​

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)
of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 12, 2025

ALTIMMUNE, INC.

(Exact name of registrant as specified in its charter)

​

​	​	​	​	​
Delaware		001-32587		20-2726770
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)
​	​	​	​	​
910 Clopper Road, Suite 201S Gaithersburg, Maryland	​	​	​	20878
(Address of principal executive offices)	​	​	​	(Zip Code)

​

Registrant’s telephone number including area code: (240) 654-1450

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

​

​	​
☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

​

Securities registered pursuant to Section 12(b) of the Act:

​

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common stock, par value $0.0001 per share	ALT	The NASDAQ Global Market

​

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

​

​

​

​

​

Item 2.02 Results of Operations and Financial Condition

On August 12, 2025, Altimmune, Inc. (the “Company”) issued a press release announcing the Company’s financial results for its second quarter ended June 30, 2025. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information included in this Current Report on Form 8-K (including Exhibit 99.1 hereto) that is furnished pursuant to this Item 2.02 shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. In addition, the information included in this Current Report on Form 8-K (including Exhibit 99.1 hereto) that is furnished pursuant to this Item 2.02 shall not be incorporated by reference into any filing of the Registrant, whether made before or after the date hereof, regardless of any general incorporation language in such filing, unless expressly incorporated by specific reference into such filing.

Item 9.01 Financial Statements and Exhibits

​

(d) Exhibits

​	​	​
No.		Description
​	​	​
99.1	​	Press Release of Altimmune, Inc. dated August 12, 2025
​	​	​
104	​	Cover Page Interactive Data File (embedded within the Inline XBRL document)

​

​

​

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

​

​	​	​	​
​	ALTIMMUNE, INC.
​	​	​	​
​	By:		/s/ Gregory Weaver
​	​		Name: Gregory Weaver
​	​		Title: Chief Financial Officer

​

Dated: August 12, 2025

​

FAQ

What did Altimmune (ALT) disclose in its latest 8-K filing?

Altimmune disclosed that it issued a press release with its financial results for the second quarter ended June 30, 2025. The press release, dated August 12, 2025, is attached as Exhibit 99.1 and is furnished rather than formally filed.

Which period do Altimmune (ALT)’s newly reported results cover?

The reported results cover Altimmune’s second quarter ended June 30, 2025. These financial results are described in a press release dated August 12, 2025, which the company furnished as Exhibit 99.1 to its current report on Form 8-K.

How did Altimmune (ALT) provide its Q2 2025 financial information?

Altimmune provided its Q2 2025 financial information through a press release dated August 12, 2025. That press release is attached as Exhibit 99.1 to a Form 8-K and is being furnished under Item 2.02 rather than treated as a filed document.

Does the Altimmune (ALT) 8-K make the press release part of other SEC filings?

No. The company states that the information in the Form 8-K, including Exhibit 99.1, will not be incorporated by reference into other SEC filings unless those filings specifically incorporate it by reference. This limits its automatic legal inclusion elsewhere.

Who signed Altimmune (ALT)’s Form 8-K for the Q2 2025 results?

The Form 8-K was signed on behalf of Altimmune, Inc. by Gregory Weaver. He is identified in the document as the company’s Chief Financial Officer, and the report is dated August 12, 2025, the same date as the related press release.

What exhibits are included with Altimmune (ALT)’s Q2 2025 8-K?

The 8-K includes two exhibits: Exhibit 99.1, which is the Altimmune, Inc. press release dated August 12, 2025, describing second-quarter 2025 financial results, and Exhibit 104, which is the cover page interactive data file embedded in the Inline XBRL document.